Pravastatin: here's the fair price
This is what US pharmacies pay, on average, for pravastatin. Use it to spot a fair cash price, and feel good about asking for one.
Pravastatin Sodium 20 Mg Tab
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Pravastatin Sodium 20 Mg Tab. Pharmacies pay about $1.70 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| PRAVASTATIN SODIUM 20 MG TABGeneric | $0.06 per tablet or capsule | $1.70 | 10/21/2026 |
| PRAVASTATIN SODIUM 10 MG TABGeneric | $0.06 per tablet or capsule | $1.72 | 10/21/2026 |
| PRAVASTATIN SODIUM 40 MG TABGeneric | $0.08 per tablet or capsule | $2.37 | 10/21/2026 |
| PRAVASTATIN SODIUM 80 MG TABGeneric | $0.14 per tablet or capsule | $4.09 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
1 INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin Sodium is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. (1.1) Reduce the risk of total...
Common side effects (FDA label)
6 ADVERSE REACTIONS Pravastatin is generally well tolerated; adverse reactions have usually been mild and transient. In 4-month-long placebo-controlled trials, 1.7% of pravastatin-treated patients and 1.2% of placebo-treated patients were discontinued from treatment because of adverse experiences attributed to study drug therapy; this difference was not statistically significant. In short-term clinical trials, the most commonly reported adverse reactions (≥2% and > placebo) regardless of causality were: musculoskeletal pain, nausea/vomiting, upper respiratory infection, diarrhea, and...
Drug interactions (from the label)
7 DRUG INTERACTIONS For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of myopathy increases [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3) ]. Concomitant lipid-lowering therapies: use with fibrates or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects. Caution should be used when prescribing with Pravastatin Sodium. (7) Cyclosporine: combination increases exposure. Limit pravastatin to 20 mg once daily. (2.6, 7.1) Clarithromycin: combination increases exposure. Limit pravastatin to 40 mg once daily. (2.7, 7.2) 7.1 Cyclosporine The risk of myopathy/rhabdomyolysis...
Warnings (from the label)
5 WARNINGS AND PRECAUTIONS Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): predisposing factors include advanced age (≥65), uncontrolled hypothyroidism, and renal impairment. Patients should be advised to promptly report to their physician any unexplained and/or persistent muscle pain, tenderness, or weakness. Pravastatin therapy should be discontinued if myopathy is diagnosed or suspected. (5.1, 8.5) Immune-Mediated Necrotizing Myopathy (IMNM): There have been rare reports of IMNM, an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment,...
Source: FDA drug label via openFDA, label effective 2024-08-14. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.